Alan Anderson

Pfizer’s decision last fall to withdraw voxelotor (Oxbryta) from the worldwide market is an example of how companies make risk-benefit calculations about medicines, and how those decisions vary widely from one category to another. Cancer drugs have their own set of standards. The risk-benefit calculus routinely accommodates uncertainty and severe side effects, if the medicine offers a modest and temporary... Read More